BlossomHill Therapeutics (NASDAQ:BLSM) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of BlossomHill Therapeutics (NASDAQ:BLSM) to a hold rating in a research report sent to investors on Saturday morning.

BlossomHill Therapeutics Stock Performance

NASDAQ:BLSM opened at $16.18 on Friday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $17.25.

Insider Buying and Selling at BlossomHill Therapeutics

In related news, Director Bihua Chen acquired 312,500 shares of the business’s stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the director directly owned 3,614,034 shares in the company, valued at $57,824,544. This represents a 9.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Carl L. Gordon purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 1,573,900 shares of company stock valued at $25,181,900 in the last quarter.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.